For countries in Europe, negotiating a deal with a pharma company over drug prices is the equivalent of a David and Goliath matchup. Payers have little leverage to push back against prices and terms set by pharma companies, causing many to accept demands for confidentiality in exchange for a discount.
Increasingly, though, some European governments are calling for an end to the secrecy in a bid to rein in drug prices.
